Results 141 to 150 of about 18,452 (302)

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension

Vascular Health and Risk Management, 2011
Zeenat SafdarDivision of Pulmonary-Critical Care Medicine, Baylor College of Medicine, Houston, Texas, USAIntroduction: Currently available endothelin receptor antagonists for treating pulmonary arterial hypertension block either the endothelin (ET ...
Safdar Z
doaj  

Vascular health and exercise in females throughout the lifespan: Exploring puberty, pregnancy and menopause

Experimental Physiology, EarlyView.
Abstract This narrative review highlights the impact of exercise on vascular health in females over the lifespan with an emphasis on puberty, pregnancy and menopause. These events encompass substantial changes in sex hormone levels, particularly oestrogens and progesterone.
Kathleen B. Miller, M. Erin Moir, Brandon G. Fico   +2 more
wiley   +1 more source

Endothelin Receptor Antagonists for Kidney Protection: Lessons from the SONAR Trial.

Clin J Am Soc Nephrol, 2022
Heerspink HJL, de Zeeuw D.
europepmc   +1 more source

Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review. [PDF]

World J Diabetes, 2020
Zhang L, Xue S, Hou J, Chen G, Xu ZG.
europepmc   +1 more source

Chronic Effects of a Novel, Orally Active Endothelin Receptor Antagonist, T-0201, in Dogs with Congestive Heart Failure

, 1998
Masato Ohnishi, Atsuyuki Wada, Takayoshi Tsutamoto, Daisuke Fukai, Masahide Sawaki, Yukiharu Maeda, Masahiko Kinoshita   +6 more
openalex   +1 more source

The therapeutic role of exercise training during menopause for reducing vascular disease

Experimental Physiology, EarlyView.
Abstract Menopause marks a major milestone in female reproductive ageing. It is characterized by the cessation of ovarian function and a concomitant decline in hormones such as oestradiol. Subsequently, females undergoing menopausal transition experience a progressive increase in cardiovascular and cerebrovascular disease risk.
Conan L. H. Shing, Bert Bond, Kerrie L. Moreau, Jeff S. Coombes, Jenna L. Taylor   +4 more
wiley   +1 more source

Dual ET_A-ET_B receptor antagonism improves metabolic syndrome-induced heart failure with preserved ejection fraction. [PDF]

Fundam Clin Pharmacol
Abstract Background Metabolic syndrome (MetS) is a multifaceted disease associated with heart failure (HF), which affects the vascular system. The endothelin (ET) system is a key player in MetS and HF; therefore, targets for ET receptors are of therapeutic interest.
Lockwood F, Lachaux M, Harouki N, Soulié M, Nicol L, Renet S, Dumesnil A, Vercauteren M, Bellien J, Iglarz M, Richard V, Mulder P.   +11 more
europepmc   +2 more sources

Cyclic Pentapeptide Endothelin A Receptor Antagonists with Attenuated in Vivo Clearance.

, 1996
Tatsuki Fukami, Kenji Niiyama, Y. Amano, Akihiro Hisaka, Naoko Fujino, Yoshio Sawasaki, M. Ihara, Kinji Ishikawa   +7 more
openalex   +2 more sources

Environmental modulators of vascular physiology and inflammation

Experimental Physiology, EarlyView.
Abstract Environmental factors play a crucial role in modulating vascular inflammation, contributing significantly to the development of atherosclerosis and cardiovascular disease. This review synthesizes current evidence on how various environmental exposures influence vascular function and inflammation, with a focus on pollutants such as particulate ...
Anusha N. Seneviratne, Anne Majumdar, Kalpana Surendranath, Mark R. Miller   +3 more
wiley   +1 more source

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension

Drug Design, Development and Therapy, 2016
Thomas J Monaco,1 Carlos D Davila2 1Division of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, 2Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA Abstract: Pulmonary arterial hypertension is a ...
Monaco TJ, Davila CD
doaj